whose treatment had consisted of fractionated radiotherapy 23 were compared with a second group of 16 patients collected independently from the first, who had undergone stereotactic radiosurgery for the same indications. All patients had undergone previous transsphenoidal surgery. The decision to use postoperative radiotherapy was generally made within the 1st postoperative year.
The first group consisted of 50 patients (25 women and 25 men) between the ages of 22.8 and 72.4 years (mean 41.3 years) who were followed for 0.6 to 21 years (mean 7.5 years). The treatments were administered between March 1973 and January 1992. The majority of patients underwent treatment at one institution (Department of Radiation Oncology, City Hospital Triemli, Zürich, Switzerland). A total dose of 40 Gy was administered in 20 fractions of 2 Gy. This treatment regimen for pituitary lesions has been published separately. 42 However, 11 patients were treated at various other institutions with doses of 44 to 56 Gy (dose per fraction 1.7-2 Gy). Additional data characterizing this group are shown in Table 3 . Two patients were treated with bromocriptine and one with octreotide at the time of radiotherapy. The octreotide-treated patient and only one of the bromocriptine-treated patients reached normal IGF-I and GH levels. Therefore, drug treatment in the second bromocriptinetreated patient must be classified as a failure.
The second group consisted of 16 patients (eight women and eight men) between the ages of 29.7 and 72.3 years (mean 48.2 years). A diagnosis of either recurrence of active acromegaly after suspected cure (three patients) or failed surgery (13 patients) was made in each of them after mid-1994. These patients underwent stereotactic radiosurgery between September 1994 and October 1996. No patient had to be rejected for treatment during this period because of technical limitations such as an adenoma diameter larger than 30 mm or adenoma touching the optic nerves or optic chiasm. Seven patients had received fractionated radiotherapy previously, but none of them had reached normal GH and IGF-I levels after a follow-up period ranging from 3 to 20 years (median 10.5 years). Five patients were being treated with octreotide (100 g subcutaneously every 8 hours) when they underwent stereotactic radiosurgery. Normal GH and IGF-I levels had been achieved in three of them; octreotide treatment failed in the other two. Three patients underwent treatment with bromocriptine (2.5 mg three times/day). None of these patients achieved normal IGF-I values, although GH levels were less than 10 mIU/L in three. The pretreatment GH and IGF-I levels in those patients who were receiving either drug when they started the study are not included in Table 3 .
The gamma knife dose planning was similar in all patients, even those who had undergone previous radiotherapy. The tumor margin, as identified on the magnetic resonance (MR) images and computerized tomography (CT) scans obtained for dose planning, received an average dose of 25 Gy (maximum dose 50 Gy). Planning was achieved by distributing several "shots" (2-21, median 12) throughout the target volume, to conform the dose to the tumor margins. Typically, small collimator sizes (4 and 8 mm) were used, and frequently source blocking was applied to obtain a sharper dose falloff toward the optic nerves and chiasm. 37 The maximum dose applied to the optic nerves and chiasm was 9 Gy or less. The lens doses were 0.6 Gy or less. The dose applied to the zone of the pituitary stalk entrance into the normal pituitary remnant ( Fig. 1 ) ranged between 9.2 and 26.8 Gy (average 16.6 Gy). The tuber cinereum was exposed to a dose of between 0.7 and 10.9 Gy (average 3.9 Gy) (Fig. 2) . The dose applied to the tumor margin had to be reduced locally in three patients: from 25 to 13.5 Gy in one patient and to 15 Gy in another (these patients had previously received 40-Gy doses of radiation) and to 20 Gy in the third patient (this patient had not previously received radiation treatment), because of the proximity of the optic nerves.
In the majority of patients, follow-up evaluation included determination of the fasting GH levels, and since 1980, IGF-I serum levels have been measured with increasing frequency. Measurements were obtained shortly before and every 3 months after patients completed the radiation treatment. Fasting GH and IGF-I levels had to range simultaneously within normal limits for the patient to be considered "normal." The plasma concentration of the GH-dependent IGF-I probably best reflects the overall regulatory influences on GH secretion. 21, 31, 36 An upper limit of less than 50 mIU/L of IGF-I and a GH level of less than 10 mIU/L in the same blood sample are used in this study to define normalized endocrine parameters. "Improvement," a term frequently used in outcome reports, means that acromegaly continues to be active, albeit possibly at a slower pace, and is thus equivalent to failure. We differentiate between only two outcome categories, "normalized endocrine parameters" and "treatment failure."
If possible, the secretory function of the remaining, normal pituitary tissue was checked at yearly intervals and/or if the patients' complaints suggested new endocrinological deficits. We measured basal serum hormone levels (cortisol, luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, T 3 , free T 4 ; and in patients younger than 50 years, estradiol and testosterone) and 24-hour urinary steroids. No function tests were performed. A particular axis was judged insufficient if substitution therapy was required.
Results
The results of the follow-up evaluations in the two groups of patients are shown as cumulative distribution functions (Kaplan-Meier estimate) in Fig. 3 . A comparison of the two curves performed by using a log-rank test 28 in which 1 df is used shows a significant difference (p Ͻ 0.0001). The mean time to normalization of the GH and IGF-I values is 7.1 years in the group treated with fractionated radiotherapy, but only 1.4 years in the group treated with stereotactic radiosurgery.
None of the three patients in the gamma knife group who were treated with doses of less than 25 Gy at the tumor margin (followed for 1.6, 1.5, and 1.3 years, respectively) has yet reached normal IGF-I and GH values.
Eleven patients underwent radiographic control examinations (10 with MR, one with CT studies) after 1 year (10 patients) or 2 years (two patients). The size of the adenoma remained unchanged in six. No correlation was found between tumor shrinkage and normalization of endocrinological parameters.
Loss of endocrine function in the normal gland was documented in eight patients (16%) of the group treated with fractionated radiotherapy. Two axes were affected in three and one axis in five patients. Five patients required cortisone, three thyroid hormone and three gonadal hormone replacement therapy (two estrogen, one testosterone). This low incidence of sex steroid replacement therapy may have been influenced by the age of the patients. No additional endocrinological deficit has been observed in the group treated with stereotactic radiosurgery.
One of our patients who received fractionated radio- therapy suffered from severe radiation-induced complications (Case 6 in Landolt 22 ). This 52-year-old woman, who had undergone unsuccessful surgery 3 months previously, received a dose of 50 Gy (25 fractions of 2 Gy). Nineteen months later, she presented with a rapidly progressing visual impairment leading to blindness, right-sided hemiparesis, and Korsakoff's syndrome. A CT scan showed an irregularly enhancing lesion in the hypothalamus, leftsided internal capsule, and lentiform nucleus that disappeared after 3 months. The patient died in a nursing home 10 years later. Postirradiation visual symptoms and other neurological sequelae have not been observed in the gamma knife group.
Discussion
The comparison of some key data (Table 3) shows that there was no significant difference in either group of patients (fractionated radiotherapy and stereotactic radiosurgery) in terms of age, sex, adenoma size, and GH and IGF-I levels before treatment. In particular, no significant differences were found in the GH and IGF-I values before surgery and radiation treatment. Postoperative persistence or recurrence of abnormal GH and IGF-I levels were the only inclusion criteria for this study. The two series were collected successively and no patient was rejected, which excludes a possible patient selection bias.
Previous studies of gamma knife-treated acromegalic patients present only end points reached after various time periods (Table 4) . No cumulative distribution curves are available yet. The results cannot be compared with ours because of the small number of patients in three of the groups and because of the different follow-up periods, radiation doses, and criteria for "cure" used. Our own criteria, that is, the simultaneous fall of the GH level to less than 10 mIU/L (5 ng/L) and that of the IGF-I level to 50 mIU/L and less, are more difficult to achieve than a simple lowering of the GH to less than 10 mIU/L. The rather disappointing results of Thorén, et al., 38 were probably caused by several factors related to their gamma knife technique, which was not as refined as current methods (imprecise target definition on skull x-ray films, wide variation of target doses, and less sophisticated dose planning), as well as larger tumor size.
Eastman and colleagues 8 did not find a difference in the postradiotherapy outcome for those patients who had previously undergone surgery compared with those who did not. This was confirmed by our extraction of the data published by Lam, et al. 18 Therefore, we have paid no attention to a possible surgical pretreatment effect when evaluating the published results obtained with fractionated radiotherapy (Table 2 ). The reported results vary considerably, and two of the main factors contributing to this variability are the different definitions of normal GH values and the different follow-up times.
The favorable outcomes obtained in the gamma knifetreated patients also may have resulted from our policy of using radiation at an early stage after unsuccessful surgery, which meant that no large tumors were encountered. In all cases debulking was performed before stereotactic radiosurgery.
The results obtained by using the gamma knife compare favorably with those obtained in our group of acromegalic patients treated with fractionated radiotherapy and with the results of fractionated radiotherapy reported in the literature ( Table 2 ). The difference is not yet evident in the long-term "final" percentage of normalized values because of the short follow-up time. However, the more rapid normalization of GH and IGF-I values after stereotactic radiosurgery is clearly evident (Fig. 3) . This considerable shortening of the postirradiation period of persistent GH elevation lessens the necessity of an expensive interval of octreotide treatment and, therefore, will be cost found by Thorén, et al., 38 in their group, which was followed for up to 20.8 years. Incomplete inclusion of the lesion because it was not visible on MR images may account for the possible failure to treat the endocrine disease.
Kliman, et al., 17 who used a single-fraction stereotactic proton-beam treatment with 12 portal entry sites and a 12-Gy central dose, achieved fasting GH levels of 10 mIU/L (5 ng/ml) in 27.5% of patients after 2 years, 56.2% after 5, 75% after 10, and 92.5% after 20 years of follow up. This treatment, therefore, normalizes GH more slowly than the gamma knife. Lawrence and colleagues 24, 25 used alpha particles applied with stereotactic techniques, at a focal dose of 8 to 10 Gy in three fractions, and achieved similar results. Growth hormone levels of less than 10 mIU/L (6 ng/L) were obtained after 2 years in 37% and after 9 or more years in 97% of patients.
The dose requirements for optimal radiosurgical treatment of pituitary adenoma remnants have not been defined. However, our observation that none of the three patients in whom the adenoma was treated with doses of less than 25 Gy to the tumor margin has demonstrated normal GH and IGF-I levels supports the findings of Backlund and Ganz.
1 These authors found in a retrospective analysis of four acromegalic patients that one patient treated with 25 Gy to the tumor edge was cured, two patients treated with 20 Gy showed improvement, and one treated with 13 Gy remained unchanged (follow-up times not indicated).
Major Types of Complications
Radiation-Induced Optic Neuropathy. This complication is dose dependent (total and fraction). Visual symptoms occur in patients treated with fractionated radiotherapy with increasing frequency if the total doses are more than 40 to 44 Gy. 10, 16, 22, 40 The latency period is 3 months to 5 years (median 9 months) posttreatment. Acromegaly may be associated with a greater risk of optic neuropathy. 16, 40 We have not yet seen a patient develop optic neuropathy after gamma knife treatment. However, our follow-up period may be too short. Ganz 11 found no visual complications in his series of 15 patients treated with the gamma knife and followed for 18 months or more, 11 and he exposed the chiasm to 4 to 15 Gy (mean 9 Gy). Stephanian, et al., 37 found no visual field changes in 12 patients who had normal fields before the gamma knife treatment. However, one patient who had received a radiation dose of 45 Gy 20 years earlier suffered a sudden deterioration of vision 7 months after undergoing stereotactic radiosurgery.
Our maximum dose of 9 Gy to the optic nerves and chiasm (8 Gy in patients who had previously received radiation treatment) seems to be high. However, this value is misleading because the partial volume exposed to this dose is not taken into account. Analysis of dose-volume histograms of critical structures near the irradiated adenoma remnant is now standard practice. We have demonstrated in a group of patients treated recently and not included in this study that doses greater than 8 Gy are limited to 2% or less of the volume of the optic nerves and chiasm.
Radiation-Induced Damage to the Remaining Normal
Pituitary Function. This complication is reported to occur as early as 1 year after fractionated radiotherapy. 19 The number of hormones affected and the incidence increases over the years. After 10 years no patient with normal function was found by Samaan, et al. 35 A lower incidence of latencies (47%) at 10 to 15 years was reported by Feek, et al. 9 The pulsatility of hormone secretion is reported to be affected primarily. Evidence for hypothalamic dysfunction was found in 76 of the 110 patients reported on by Samaan, et al., whereas pituitary damage was found in only 43. The levels of all pituitary hormones except prolactin were lowered; because of the lack of dopaminergic inhibition, prolactin was raised. The doses delivered to the hypothalamus ranged between 35 and 45 Gy of fractionated radiation in the patients treated by Lam, et al., 19 whereas Samaan, et al., used 18 to 70 Gy of fractionated radiation (in patients with nasopharyngeal carcinoma). Our low incidence of postradiotherapy pituitary dysfunction (16%) is explained by the fact that no dynamic tests were performed. Pituitary insufficiency was judged exclusively by the patient's need for hormone replacement therapy. This reduces the size of the group of patients needing gonadal hormone replacement therapy because of the elimination of patients 50 years or older (postfertility phase). Thus far we have not found cases of additional pituitary or hypothalamic dysfunction in our patients who received single-dose stereotactic radiosurgery. It is not yet clear if this is a result of the much lower doses to the hypothalamus with stereotactic radiosurgery (0.7-10.9 Gy) or the shorter follow-up time.
Conclusions
Stereotactic radiosurgery offers a safe and efficient treatment for recurrent or surgically uncured acromegaly. Normalization of GH and IGF-I values occurs significantly faster than with fractionated radiotherapy; 50% of the treated patients show normalized hormone levels 1.4 years after stereotactic radiosurgery and 7.1 years after fractionated radiotherapy. No radiation-induced complications (such as optic nerve neuropathy, pituitary and hypothalamic dysfunction) have been observed yet in our group of 16 patients followed up for periods ranging between 6 
